Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma

Manzar Alam; Gulam Mustafa Hasan; Sayed M Eldin; Mohd Adnan; Muhammad Bilal Riaz; Asimul Islam; Ilyas Khan; Md Imtaiyaz Hassan

doi:10.1016/j.biopha.2023.114452

Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma

Biomed Pharmacother. 2023 May:161:114452. doi: 10.1016/j.biopha.2023.114452. Epub 2023 Mar 4.

Authors

Manzar Alam¹, Gulam Mustafa Hasan², Sayed M Eldin³, Mohd Adnan⁴, Muhammad Bilal Riaz⁵, Asimul Islam¹, Ilyas Khan⁶, Md Imtaiyaz Hassan⁷

Affiliations

¹ Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India.
² Department of Biochemistry, College of Medicine, Prince Sattam Bin Abdulaziz University, P.O. Box 173, Al-Kharj 11942, Saudi Arabia.
³ Center of Research, Faculty of Engineering, Future University in Egypt, New Cairo 11835, Egypt.
⁴ Department of Biology, College of Science, University of Hail, Hail, Saudi Arabia.
⁵ Faculty of Applied Physics and Mathematics, Gdansk University of Technology, Narutowicza 11/12, 80-233 Gdnask, Poland; Department of Computer Science and Mathematics, Lebanese American University, Byblos, Lebanon.
⁶ Department of Mathematics, College of Science Al-Zulfi, Majmaah University, Al-Majmaah 11952, Saudi Arabia. Electronic address: i.said@mu.edu.sa.
⁷ Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India. Electronic address: mihassan@jmi.ac.in.

PMID: 36878052
DOI: 10.1016/j.biopha.2023.114452

Abstract

Non-small cell lung carcinoma (NSCLC) is the most common malignancy worldwide. The signaling cascades are stimulated via genetic modifications in upstream signaling molecules, which affect apoptotic, proliferative, and differentiation pathways. Dysregulation of these signaling cascades causes cancer-initiating cell proliferation, cancer development, and drug resistance. Numerous efforts in the treatment of NSCLC have been undertaken in the past few decades, enhancing our understanding of the mechanisms of cancer development and moving forward to develop effective therapeutic approaches. Modifications of transcription factors and connected pathways are utilized to develop new treatment options for NSCLC. Developing designed inhibitors targeting specific cellular signaling pathways in tumor progression has been recommended for the therapeutic management of NSCLC. This comprehensive review provided deeper mechanistic insights into the molecular mechanism of action of various signaling molecules and their targeting in the clinical management of NSCLC.

Keywords: Apoptosis; Cancer signaling; Non-small cell lung carcinoma; Small molecule inhibitors; Targeted therapy, Drug development.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung* / pathology
Cell Line, Tumor
Cell Proliferation
Humans
Lung Neoplasms* / pathology
Signal Transduction